Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2017-10-24

FDA Approved: KEPPRA — Supplemental Application (UCB, Inc.)

View source ↗

Summary

FDA page indicating a supplemental application for KEPPRA (levetiracetam) by UCB, Inc. under NDA 021035.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Keppra (levetiracetam)

Snippet

SUPPL AP for KEPPRA (LEVETIRACETAM)